PIK3CG-degrading PROTAC for AML

A proteolytic targeting chimera (PROTAC) that degrades PIK3CG — a myeloid specific PI3K isoform that promotes innate immunity and immune evasion in cancer — could help treat AML by decreasing AKT signaling, resulting in increased cell death and decreased resistance to the BCL-2 inhibitor Venclexta venetoclax.

In publicly available AML patient data, PIK3CG mRNA expression was higher in AML cells compared with other cell types, and high myeloid PIK3CG expression was associated with increased resistance to Venclexta. ...